ZEPP:NYSEZepp Health Corporation Analysis

Zepp Health (ZEPP) is trading at the identified support level of $11.29, with the 20‑day SMA ($15.84) still above the 50‑day SMA ($15.44) indicating a short‑term downtrend that may be stabilizing. The RSI of 32 suggests the stock is oversold, while the MACD remains bearish (histogram –0.49), reinforcing a cautious technical outlook. Market sentiment is at an Extreme Greed level (Fear‑Greed Index 87.98), which could fuel speculative buying despite the weak fundamentals.
On the fundamentals side, ZEPP posted a robust 43% revenue growth year‑over‑year, yet margins are deep in the red (operating margin –4.5%, profit margin –15.5%) and cash flow remains negative. The forward P/E of 161.3 dwarfs the industry average of 39, reflecting earnings pressure, while the price‑to‑book (0.84) and price‑to‑sales (0.64) ratios appear cheap relative to assets. High volatility (115% 30‑day) and a beta of 1.5 indicate heightened price swings, and a sizable debt load (≈$117 M) adds financial strain. Overall, the stock sits at a potential upside of >300% based on price targets, but the path to that upside hinges on turning the cash‑burn into profitability.